Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: zx who wrote (29016)	3/15/2006 2:20:51 PM
From: blind-geezer	Read Replies (1) \| Respond to of 48463

dude, I am not buying any more on this one after 1 50% haircut ... just find out that the CEO's name is Pussy, what kind of a name is that ...

To: zx who wrote (29016)	3/19/2006 3:08:04 AM
From: tsigprofit	Read Replies (2) \| Respond to of 48463

OLGC - no, I sold out of that in late November, too early as it turns out, but I made a small profit on it then - about 10% on the October to November run last year. Haven't had it since. Haven't started another position since this big plunge, but that might not be a bad idea. Saw this when reading about it today after I saw your post: Making matters worse, this was the company's only advanced clinical study currently under way. OrthoLogic is working on a formulation of Chrysalin for the treatment of diabetic wounds, and it recently acquired a preclinical compound that might be useful in vasospasm, the prevention of keloid scarring, and asthma -- but both of those compounds are many years away from approval (assuming they work). The good news, such as it is, is that OrthoLogic has a pretty decent chunk of cash on the balance sheet. Presuming, for the moment, that the company will abandon studies of Chrysalin in fracture care, it should have at least a few years of cash burn before it would have to raise money again. On the down side, I'm not sure there's much for investors to look forward to -- aside, perhaps, from the initiation of clinical studies on a gel formulation of Chrysalin for foot ulcers (and eventual results of such studies). Not to beat a dead horse, or a half-dead company, but here again we're reminded of the risks of one-trick biotech ponies -- other examples are Axonyx (Nasdaq: AXYX) and Pharmos (Nasdaq: PARS). Biotech investing is hard enough on its own, so don't make it even harder by depending upon risky concepts. Instead, look for stocks like Neurocrine Biosciences (Nasdaq: NBIX), DOV Pharmaceuticals (Nasdaq: DOVP), and Acadia (Nasdaq: ACAD) to enjoy the fruits of companies with multiple irons in the fire. fool.com